The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2/3 study of bicycle toxin conjugate zelenectide pevedotin (BT8009) targeting Nectin-4 in patients with locally advanced or metastatic urothelial cancer (la/mUC) (Duravelo-2).
 
Yohann Loriot
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Gilead Sciences; Janssen; Loxo/Lilly; Merck KGaA; MSD Oncology; MSD Oncology (Inst); Pfizer (Inst); Pfizer/EMD Serono; Roche; Roche (Inst); Seagen; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); BMS (Inst); Exelixis (Inst); Gilead Sciences (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck KGaA (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Tyra Biosciences (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Janssen Oncology; MSD Oncology; Roche; Seagen
 
Arlene Siefker-Radtke
Consulting or Advisory Role - Abbvie; Astellas Pharma; Bicycle Therapeutics; G1 Therapeutics; Gilead Sciences; Immunomedics; Janssen; Loxo; Merck; Pfizer; Seagen; Taiho Pharmaceutical
Research Funding - Basilea (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Loxo (Inst); Merck (Inst); Millennium (Inst); Nektar (Inst)
 
Terence Friedlander
Honoraria - Abbvie; Astellas Pharma; EMD Serono; Merck
Consulting or Advisory Role - AADi; Astellas Pharma; Atkis; Bicycle Therapeutics; Bristol-Myers Squibb/Medarex; EMD Serono; Gilead Sciences; Janssen; Merck; Seagen
Research Funding - Bicycle Therapeutics; Bristol-Myers Squibb (Inst); Neon Therapeutics (Inst); Roche/Genentech (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bicycle Therapeutics; Merck
 
Andrea Necchi
Employment - Bayer (I)
Stock and Other Ownership Interests - Bayer (I)
Consulting or Advisory Role - AstraZeneca; Bicycle Therapeutics; Bristol-Myers Squibb; Catalym; Genenta Science; Gilead Sciences; Incyte; Johnson & Johnson/Janssen; Merck Serono; Merck Sharp & Dohme; Peerview; PeerVoice; Samsung Bioepis; Seattle Genetics/Astellas
Research Funding - Bristol-Myers Squibb/Celgene (Inst); Gilead Sciences (Inst); Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Gilead Sciences; Janssen; Merck Sharp & Dohme
 
Alexander Wei
Research Funding - IDEAYA Biosciences (Inst); Novartis (Inst); Pyxis (Inst); Regeneron (Inst)
 
Srikala Sridhar
Consulting or Advisory Role - AstraZeneca (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Gilead Sciences (Inst); Janssen (Inst); Merck (Inst); Pfizer (Inst); Seagen (Inst)
Research Funding - Bayer (Inst); Janssen (Inst); Pfizer (Inst)
 
Benjamin Garmezy
Research Funding - Abbvie (Inst); Accutar Biotech (Inst); Arcus Biosciences (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); AVEO (Inst); crispr therapeutics (Inst); Eikon Therapuetics (Inst); Envision Pharma Group (Inst); Exelixis (Inst); Flare Therapeutics (Inst); Genentech (Inst); Harbour BioMed (Inst); IDEAYA Biosciences (Inst); Janssen Oncology (Inst); Janux Therapeutics (Inst); Jubilant Therapeutics (Inst); Kineta (Inst); Kinnate Biopharma (Inst); Loxo (Inst); Loxo/Lilly (Inst); MiNK Therapeutics (Inst); Nuvation Bio (Inst); ProfoundBio (Inst); Roche/Genentech (Inst); Takeda (Inst); Teon Therapeutics (Inst); Tmunity Therapeutics, Inc. (Inst); Xencor (Inst); Xencor (Inst); Zenshine (Inst); Zenshine (Inst)
(OPTIONAL) Uncompensated Relationships - Abbvie (Inst); Adaptimmune (Inst); Adicet Bio (Inst); AIQ Global (Inst); Amgen (Inst); Arcus Biosciences (Inst); Arvinas (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); Eisai (Inst); EMD Serono (Inst); Exelixis (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Rondo Therapeutics (Inst); Sanofi (Inst); Seagen (Inst); Xencor (Inst)
 
Santiago Arroyo
Employment - Bicycle Therapeutics
Leadership - Bicycle Therapeutics
Stock and Other Ownership Interests - Bicycle Therapeutics
Honoraria - Bicycle Therapeutics
Consulting or Advisory Role - Bicycle Therapeutics
Patents, Royalties, Other Intellectual Property - Bicycle Therapeutics
Travel, Accommodations, Expenses - Bicycle Therapeutics
 
Emma Gartside
Employment - Bicycle Therapeutics
Stock and Other Ownership Interests - Bicycle Therapeutics; Roche
 
Jie Liu
Employment - Bicycle Therapeutics
 
Carly Campbell
Employment - Bicycle Therapeutics
Stock and Other Ownership Interests - Bicycle Therapeutics; Epizyme
 
Justin Bader
Employment - Bicycle Therapeutics
Stock and Other Ownership Interests - Bicycle Therapeutics
 
Daniel Petrylak
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bicycle Therapeutics; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Gilead Sciences; Incyte; Ipsen; Janssen; Lilly; Mirati Therapeutics; Monopteros Therapeutics; Pfizer; Pharmacyclics; Regeneron; Roche; Seagen; Urogen pharma
Research Funding - Advanced Accelerator Applications (Inst); Agensys (Inst); Astellas Medivation (Inst); AstraZeneca (Inst); Bayer (Inst); BioXCel therapeutics (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); Endocyte (Inst); Genentech (Inst); Gilead Sciences (Inst); Innocrin Pharma (Inst); Lilly (Inst); MedImmune (Inst); Medivation (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Progenics (Inst); Replimune (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst)
Expert Testimony - Celgene; sanofi